We're used to the idea, honestly, of paying millions of dollars to treat people with a disease,

but we're not used to paying it to a drug company.

We're used to paying it to physicians and hospitals and healthcare systems.

Right?

So all of these are paradigm shifts.

And when you're talking about that kind of paradigm shift, one thing to remember is that

the innovator actually has a lot of brush to clear away in terms of regulation, reimbursement,

physician habits, and more.

And the followers kind of benefit from that.

I'm Chris Hill, and that's Motley Fool Advisor Carl Teal.

Today we're talking about CRISPR and the exciting frontiers of genetic cures.

Ricky Mulvey caught up with Carl to talk about how CRISPR actually works, the endless possibilities

for this technology, including drought-resistant crops.

And how investors should approach this promising yet incredibly complex space.

The era of the gene-edited human is here.

Whether that scares you or not, scares me a little bit, so today we're talking about

CRISPR and the exciting frontiers of gene-editing technologies.

Joining us now, Motley Fool Advisor Carl Teal.

Thanks for being here.

Great, thanks for having me.

This is fun stuff to talk about.

It's going to get weird, so buckle up.

...